JPMorgan on ORIC Pharmaceuticals (ORIC): 'We Are Buyers On Weakness'

March 11, 2026 10:00 AM EDT Send to a Friend
JPMorgan analyst Anupam Rama reiterated an Overweight rating and $21.00 price target on ORIC Pharmaceuticals (NASDAQ: ORIC).The analyst comments "Net-net ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login